For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine. “Yet there are not many, if any, drugs that specifically target metastatic processes."
Conferences
Long-Term Biologic Use May Not Raise Melanoma Risk
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis.
Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.
Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma
Encorafenib (Braftovi) plus binimetinib (Mektovi) show sustained overall survival (OS) and progression-free survival (PFS) benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS (NCT01909453) study, presented in a poster at the 2020 American Society of Clinical Oncology Virtual Scientific Program.